Merck & Co., Inc. (MRK) Tops Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Price: $146.87 -0.19%
EPS Growth %: -14.0%
Financial Fact:
Materials and production: 5.59B
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -14.0%
Financial Fact:
Materials and production: 5.59B
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Merck & Co., Inc. (NYSE: MRK) reported Q3 EPS of $0.94, $0.03 better than the analyst estimate of $0.91. Revenue for the quarter came in at $12 million versus the consensus estimate of $11.61 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU panel backs Merck's Keytruda plus Padcev for bladder cancer
- Saudi Arabia shuts East-West Pipeline after attacks
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIB
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
